Skip to main content
. 2023 Sep 15;13:1200619. doi: 10.3389/fonc.2023.1200619

Figure 1.

Figure 1

PD-1/PD-L1 antibodies target two endpoints of the same immune pathway and therefore have very different mechanisms of action and clinical efficacy. DC, Dendritic cells; TCR, T cell receptor; CD, Cluster of differentiation; PD, Programmed cell death protein; PD-L, Programmed cell death ligand; MHC, Major histocompatibility complex.